Disease Overview：Henoch-Schönlein purpura nephritis（HSPN）
Henoch-Schönlein purpura nephritis (HSPN) is an immune-mediated small-vessel vasculitis affecting the kidneys, typically following systemic Henoch-Schönlein purpura (HSP). It results from IgA-dominant immune complex deposition in the glomeruli, leading to mesangial proliferation, hematuria, proteinuria, and—depending on histopathological severity—progressive renal dysfunction. Clinical presentation ranges from isolated microscopic hematuria to nephrotic syndrome or rapidly progressive glomerulonephritis. Diagnosis relies on clinical correlation, urinalysis, serum IgA levels, complement profiling, and often renal biopsy for Oxford MEST-C classification to guide prognosis and therapy. Treatment is stratified by risk: low-risk cases may require only supportive care and ACE inhibitors; moderate-to-high-risk disease often necessitates corticosteroids, mycophenolate mofetil, or cyclophosphamide, with emerging evidence supporting rituximab in refractory cases. Long-term monitoring of eGFR, proteinuria, and histologic response is essential to prevent chronic kidney disease progression.
China offers distinct advantages in HSPN management: leading nephrology centers—such as Peking University First Hospital and Shanghai Renji Hospital—maintain dedicated IgA nephropathy/HSPN research units with extensive clinical trial participation and standardized treatment protocols aligned with KDIGO guidelines. Advanced diagnostics include digital pathology integration, mass spectrometry–based IgA1 glycosylation profiling, and real-time eGFR trajectory modeling. Over 85% of patients with mild-to-moderate HSPN achieve sustained remission within 12 months under protocol-driven regimens. Cost-wise, comprehensive evaluation and 6-month immunosuppressive therapy in China average 40–60% less than equivalent care in the US or Western Europe—without compromising quality or outcomes. As a medical tourism agency, we facilitate seamless access to these specialized programs: verifying physician credentials, coordinating biopsy scheduling and multidisciplinary review, providing itemized, upfront pricing in USD, and delivering end-to-end support—from visa assistance and accommodation to post-discharge teleconsultation and medication logistics.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Henoch-Schönlein Purpura Nephritis (HSPN)
Non-Surgical / Conservative Management
*Target Criteria:* Mild–moderate proteinuria (<1 g/day), normal eGFR, no crescents on biopsy, pediatric or adult patients without rapid progression.
- •First-line immunosuppression (oral corticosteroids)
- •Adjunctive agents
- Azathioprine (if MMF contraindicated): $150–$230
- •Supportive care
- Antihypertensives (amlodipine, if needed): $25–$40
- •Monitoring labs & exams (per 3-month cycle)
- Serum creatinine, eGFR, albumin, IgA, C3: $32 - Renal ultrasound: $48 - *Annual renal biopsy (if indicated for progression)*: $320
Surgical / Procedural / Interventional Options
*Eligibility Criteria:* Crescents >50% on biopsy, rapidly declining eGFR (<60 mL/min/1.73m²), nephrotic-range proteinuria (>3.5 g/day), steroid resistance.
- •Pulse methylprednisolone (3-day IV course)
- •Cyclophosphamide pulse therapy (6 monthly IV doses)
- Total 6-dose course: $2,280–$3,120
- •Plasma exchange (PLEX)
- Typical course (7 sessions over 2 weeks): $3,220–$4,410
- •Preoperative workup (required before PLEX or cyclophosphamide)
- Central venous catheter placement (if needed): $270
Special / Complex Condition Management
- •Refractory HSPN with ESRD
- •HSPN with severe gastrointestinal vasculitis requiring urgent intervention
- •Pediatric HSPN with steroid-dependent relapse
Quick Selection Guide
- •Children <12 years, mild proteinuria (<0.5 g/day), no hypertension: Start with ACEi + prednisone ($120–$180); avoid cytotoxics unless crescentic.
- •Adults 18–50, crescentic biopsy (>30%), eGFR 45–59 mL/min: Cyclophosphamide pulses + PLEX ($5,500–$7,530 total) preferred over rituximab due to stronger evidence in HSPN.
- •Budget-constrained adults (≤$1,000 total): MMF + ACEi + strict monitoring ($600–$850)—avoid PLEX/cyclophosphamide unless life-threatening.
- •Elderly (>65) with diabetes/hypertension comorbidity: Prioritize low-dose prednisone + ACEi + rigorous BP control ($200–$350); defer cytotoxics unless fulminant.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Henoch-Schönlein purpura nephritis Medical Vacation Packages
Curated transparent all-inclusive packages combining Henoch-Schönlein purpura nephritis treatment with China top medical destinations:
